Key Assay Development at HUPO

RNS Number : 3199O

Proteome Sciences PLC

18 September 2013

 



Proteome Sciences plc

("Proteome Sciences" or the "Company")

Key Assay Development at HUPO

18^th September, 2013.  Proteome Sciences presented novel data and key assay developments at the HUPO 12^th Annual World Congress in Japan covering Tau in Alzheimer's disease, SysQuant^® in pancreatic cancer and a missing isoform in sugar structures of clusterin, a plasma protein biomarker for Alzheimer's in brain atrophy.

pTau

The new Tau phosphorylation assay (pTau SRM) demonstrated powerful sensitivity and reproductivity measuring Tau phosphorylation on human and mouse models of Alzheimer's disease from a much smaller sample amount.

In a different application the pTau SRM was successfully used to determine the effect of Tau kinase inhibitors PS110 and PS278-05 on CK1d on the Tau protein in a mouse model of Alzheimer's.  The results confirmed that Tau phosphorylation was reduced by the two compounds but not affected by the control substance.

SysQuant^®

Over 5,000 different phosphorylation sites were quantified in tumour and healthy tissue in pancreas cancer with SysQuant^®.  In addition to major alterations in proteins related to cell morphology and motility, individual patterns of pathway activation were able to accurately predict the likelihood of tumour recurrence and to provide a truly personalised treatment regime.

Glycopreotomics

Novel data was presented that showed diagnostic changes in sugar structures attached to clusterin, a plasma marker for Alzheimer's in brain atrophy.  This revealed a unique isoform that lacked a specific branching pattern in patients with high levels of brain atrophy.

Commenting from Yokohama, Dr. Ian Pike, Chief Operating Officer, said:

"We were delighted to be invited to the 12^th HUPO congress to show results from the powerful biomarker services platform that we have developed from our TMT^® mass tags for customers where we are at the forefront in proteomics.

New assays for pTau and clusterin glycoprotein provide important additions to the range of assays and services that we offer our customers in Alzheimer's  The added power delivered by SysQuant^® identifies thousands of phosphorylation sites across key signalling pathways that give clinicians the ability for the first time to provide real time patient management, in this case in pancreas cancer,

These are exciting developments from proteomics that are fundamentally changing how clinicians identify and manage disease."

- Ends -

For further information please contact:

Proteome Sciences plc
Christopher Pearce, Chief Executive Officer	Tel: [phone]
Dr. Ian Pike, Chief Operating Officer James Malthouse, Finance Director
Nominated Adviser
Cenkos
Stephen Keys/Camilla Hume	Tel: [phone]
Public Relations
IKON Associates
Adrian Shaw
Tel: [phone]

Notes to Editors:

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag^® (TMT^®) workflows developed on the latest Orbitrap^® Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT^® workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.

Visit:  http://www.proteomics.com

 

END

 

 

MSCBBGDCISBBGXI